Cargando…
Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
This review focuses on the evidence for neurotherapeutics for attention deficit/hyperactivity disorder (ADHD). EEG-neurofeedback has been tested for about 45 years, with the latest meta-analyses of randomised controlled trials (RCT) showing small/medium effects compared to non-active controls only....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394071/ https://www.ncbi.nlm.nih.gov/pubmed/34440925 http://dx.doi.org/10.3390/cells10082156 |
_version_ | 1783743864800018432 |
---|---|
author | Rubia, Katya Westwood, Samuel Aggensteiner, Pascal-M. Brandeis, Daniel |
author_facet | Rubia, Katya Westwood, Samuel Aggensteiner, Pascal-M. Brandeis, Daniel |
author_sort | Rubia, Katya |
collection | PubMed |
description | This review focuses on the evidence for neurotherapeutics for attention deficit/hyperactivity disorder (ADHD). EEG-neurofeedback has been tested for about 45 years, with the latest meta-analyses of randomised controlled trials (RCT) showing small/medium effects compared to non-active controls only. Three small studies piloted neurofeedback of frontal activations in ADHD using functional magnetic resonance imaging or near-infrared spectroscopy, finding no superior effects over control conditions. Brain stimulation has been applied to ADHD using mostly repetitive transcranial magnetic and direct current stimulation (rTMS/tDCS). rTMS has shown mostly negative findings on improving cognition or symptoms. Meta-analyses of tDCS studies targeting mostly the dorsolateral prefrontal cortex show small effects on cognitive improvements with only two out of three studies showing clinical improvements. Trigeminal nerve stimulation has been shown to improve ADHD symptoms with medium effect in one RCT. Modern neurotherapeutics are attractive due to their relative safety and potential neuroplastic effects. However, they need to be thoroughly tested for clinical and cognitive efficacy across settings and beyond core symptoms and for their potential for individualised treatment. |
format | Online Article Text |
id | pubmed-8394071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83940712021-08-28 Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review Rubia, Katya Westwood, Samuel Aggensteiner, Pascal-M. Brandeis, Daniel Cells Review This review focuses on the evidence for neurotherapeutics for attention deficit/hyperactivity disorder (ADHD). EEG-neurofeedback has been tested for about 45 years, with the latest meta-analyses of randomised controlled trials (RCT) showing small/medium effects compared to non-active controls only. Three small studies piloted neurofeedback of frontal activations in ADHD using functional magnetic resonance imaging or near-infrared spectroscopy, finding no superior effects over control conditions. Brain stimulation has been applied to ADHD using mostly repetitive transcranial magnetic and direct current stimulation (rTMS/tDCS). rTMS has shown mostly negative findings on improving cognition or symptoms. Meta-analyses of tDCS studies targeting mostly the dorsolateral prefrontal cortex show small effects on cognitive improvements with only two out of three studies showing clinical improvements. Trigeminal nerve stimulation has been shown to improve ADHD symptoms with medium effect in one RCT. Modern neurotherapeutics are attractive due to their relative safety and potential neuroplastic effects. However, they need to be thoroughly tested for clinical and cognitive efficacy across settings and beyond core symptoms and for their potential for individualised treatment. MDPI 2021-08-21 /pmc/articles/PMC8394071/ /pubmed/34440925 http://dx.doi.org/10.3390/cells10082156 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rubia, Katya Westwood, Samuel Aggensteiner, Pascal-M. Brandeis, Daniel Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review |
title | Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review |
title_full | Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review |
title_fullStr | Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review |
title_full_unstemmed | Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review |
title_short | Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review |
title_sort | neurotherapeutics for attention deficit/hyperactivity disorder (adhd): a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394071/ https://www.ncbi.nlm.nih.gov/pubmed/34440925 http://dx.doi.org/10.3390/cells10082156 |
work_keys_str_mv | AT rubiakatya neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview AT westwoodsamuel neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview AT aggensteinerpascalm neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview AT brandeisdaniel neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview |